ABSTRACT

The preceding chapters of this monograph have demonstrated that the inhibition of poly(ADP-ribose) polymerase-1 (PARP-1) during acute genotoxic stress could potentially alleviate human suffering associated with many diseases. Although many lessons have been learned, the realization of the goal of targeting PARP-1 for therapeutic benefit has not yet been reached and much remains to be accomplished. In this closing chapter, we speculate on both future challenges and future opportunities that may lie ahead for this emerging area of therapeutics.